Trv Gp Vi LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX

Trv Gp Vi LLC bought a new stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 194,174 shares of the company’s stock, valued at approximately $6,069,879. Tango Therapeutics makes up 0.0% of Trv Gp Vi LLC’s portfolio, making the stock its 4th biggest position. Trv Gp Vi LLC owned approximately 0.13% of Tango Therapeutics at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of TNGX. Global Retirement Partners LLC acquired a new position in shares of Tango Therapeutics during the 4th quarter worth about $35,000. Dynamic Technology Lab Private Ltd increased its position in shares of Tango Therapeutics by 139.7% during the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock valued at $35,000 after buying an additional 15,037 shares during the period. Legal & General Group Plc grew its holdings in shares of Tango Therapeutics by 30.7% in the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock worth $36,000 after purchasing an additional 1,640 shares during the last quarter. ANTIPODES PARTNERS Ltd bought a new position in Tango Therapeutics during the 4th quarter valued at approximately $40,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Tango Therapeutics by 148,800.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock valued at $40,000 after buying an additional 4,464 shares during the period. 78.99% of the stock is currently owned by institutional investors.

Tango Therapeutics Trading Down 6.0%

Shares of NASDAQ TNGX traded down $1.51 during midday trading on Friday, hitting $23.77. The company’s stock had a trading volume of 832,270 shares, compared to its average volume of 3,433,863. The firm has a market cap of $4.01 billion, a P/E ratio of -27.96 and a beta of 1.16. The business’s 50 day moving average is $27.84 and its two-hundred day moving average is $23.13. Tango Therapeutics, Inc. has a 12-month low of $6.25 and a 12-month high of $34.39.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.05). On average, analysts predict that Tango Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TNGX has been the topic of several recent analyst reports. Piper Sandler downgraded shares of Tango Therapeutics from an “overweight” rating to a “neutral” rating and upped their price objective for the company from $16.00 to $24.00 in a report on Thursday, May 14th. Jefferies Financial Group raised shares of Tango Therapeutics from a “hold” rating to a “buy” rating and boosted their target price for the stock from $27.00 to $60.00 in a research report on Thursday, June 25th. Weiss Ratings raised Tango Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Wall Street Zen cut shares of Tango Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Finally, Leerink Partners lifted their price target on Tango Therapeutics from $55.00 to $69.00 and gave the stock an “outperform” rating in a report on Monday, June 8th. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Tango Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.46.

Insiders Place Their Bets

In related news, insider Adam Crystal sold 27,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total value of $798,930.00. Following the transaction, the insider directly owned 115,743 shares of the company’s stock, valued at approximately $3,424,835.37. This trade represents a 18.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.50% of the company’s stock.

Tango Therapeutics Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.